Ultime notizie per Joint (NASDAQ:JYNT) Azioni

Joint

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

The Joint Corp

Roth MKM analyst George Kelly maintains Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) with a Buy and lowers the price target from $16 to $15.

News

Price Target

Analyst Ratings

JYNT

Roth MKM Maintains Buy on Joint, Lowers Price Target to $15

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 180 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $30.198 million which beat the analyst consensus estimate of $28.376 million by 6.42 percent. This is a 2.46 percent increase over sales of $29.474 million the same period last year.

Earnings

Earnings Beats

Joint Q3 2024 Adj. EPS $0.04 Beats $0.01 Estimate, Sales $30.198M Beat $28.376M Estimate

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) System-wide sales are expected to be between $525 million and $535 million.

Guidance

Joint Corp. FY 2024 System-wide sales are expected to be between $525 million and $535 million.

Management

The Joint Corp Appoints Sanjiv Razdan As Its President And CEO, Effective Today; Peter Holt Resigns

<ul>
<li>System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024.</li>
<li>New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 60 and 75, compared to 104 in 2023.</li>
</ul>

The Joint Corp Reiterates All Elements Of Its FY24 Guidance; Expects System-Wide Sales To Be $530M - $545M

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.02) by 200 percent. The company reported quarterly sales of $30.261 million which beat the analyst consensus estimate of $29.397 million by 2.94 percent. This is a 3.26 percent increase over sales of $29.307 million the same period last year.

Earnings Misses

Joint Q2 2024 Adj. EPS $(0.06) Misses $(0.02) Estimate, Sales $30.261M Beat $29.397M Estimate

Quest Diagnostics (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) has entered into a definitive agreement with OMERS to acquire LifeLabs, a prominent Canadian provider of community laboratory tests. The deal, valued at approximately CAN $1.35 billion ($985 million), underscores DGX&#39;s strategy to expand its footprint in Canada&#39;s healthcare diagnostics market.
By integrating LifeLabs into its operations, Quest Diagnostics aims to enhance the accessibility and quality of diagnostic services for Canadians.
Investors should note that OMERS, a jointly sponsored, defined benefit pension plan, purchased LifeLabs back in 2007.
<h3>Terms and Strategic Vision</h3>
Under the latest agreement, Quest Diagnostics will acquire 100% of LifeLabs&#39; equity, funding the transaction through cash and debt. The acquisition is expected to generate annual revenues of approximately CAN $970 million ($710 million) and will be slightly dilutive to Quest Diagnostics&#39; GAAP EPS due to amortization. However, it will be accretive to adjusted EPS within the first year after closing.
LifeLabs will retain its brand, headquarters and management, ensuring continuity in its operations while benefiting from Quest&#39;s expertise and innovations.
<h3>Synergy Benefits</h3>
The acquisition promises several synergy benefits. Quest Diagnostics&#39; extensive experience and resources will bolster LifeLabs&#39; service offerings. This includes enhanced online appointment scheduling and quicker patient service center processing. Additionally, Quest Diagnostics plans to accelerate LifeLabs&#39; data security measures, ensuring that Canadian patients&#39; health data remains secure and within the country.
Quest Diagnostics&#39; recent advancements in specialized testing for Alzheimer&#39;s disease, women&#39;s health, oncology and cardiometabolic health will also be integrated into LifeLabs&#39; services. This will provide Canadians with access to cutting-edge diagnostics, enhancing overall healthcare delivery.
<h3>Strengthening Collaboration</h3>
The five-year long-established relationship between Quest Diagnostics and LifeLabs, through the Global Diagnostic Network and reference testing agreements, sets a strong foundation for this acquisition. This existing collaboration has already facilitated the sharing of expertise and broadened testing access, which will be further amplified post-acquisition.
By leveraging Quest&#39;s innovations and LifeLabs&#39; established presence, the partnership aims to meet the growing healthcare needs of Canadians, driving improved health outcomes and service efficiency.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2a/70342.jpg?v=1935716916" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h3>Industry Prospects</h3>
According to an Insights 10 report, the clinical diagnostics market in Canada is poised for substantial growth. It is projected to rise from $3.9 billion in 2022 to $4.9 billion by 2030 at a CAGR of 3.1%. This growth is likely to be driven by increased awareness of early disease detection and treatment benefits, alongside significant government investments in diagnostic services. Key players such as LifeLabs, SickKids and Dynacare dominate the market, which is segmented by molecular diagnostics and end users. Government initiatives, like Bill C-17, further bolster the market&#39;s expansion by providing additional funding for healthcare improvements.
<h3>Share Price Performance</h3>
Year to date, shares of DGX have risen 2.2% compared with the industry&#39;s 5.7% growth.
<h3>Zacks Rank and Key Picks</h3>
Quest Diagnostics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>), The Joint Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jynt#NASDAQ">JYNT</a>) and Medpace Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>). While Hims &amp; Hers and The Joint currently sport a Zacks Rank #1 (Strong Buy) each, Medpace Holdings carries a Zacks Rank #2 (Buy) at present.
The Hims &amp; Hers Heath stock has surged 130.5% in the past year. Estimates for the company&#39;s 2024 earnings have moved north by 5.6% to 19 cents per share in the past 30 days.
HIMS&#39; earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for The Joint&#39;s 2024 earnings per share have remained constant at 21 cents in the past 30 days. Shares of JYNT have surged 38.8% year to date against the industry&#39;s 5.3% decline.
In the last reported quarter, JYNT delivered an earnings surprise of 300%. It has a trailing four-quarter average earnings surprise of 18.75%.
Estimates for Medpace&#39;s 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have surged 70.1% in the past year compared with the industry&#39;s 4.6% growth.
MEDP&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
<a href="https://www.zacks.com/stock/news/2296967/quest-diagnostics-dgx-to-expand-in-canada-with-lifelabs-buyout?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2296967">To read this article on Zacks.com click here.</a>

Health Care

Markets

Trading Ideas

General

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MEDP

Quest Diagnostics to Expand in Canada With LifeLabs Buyout

Neuronetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stim#NASDAQ">STIM</a>) recently announced the nationwide launch of the Better Me Provider (BMP) program. The BMP program will be a part of the company&#39;s NeuroStar product line. The providers participating in the program are expected to maintain correct standards, developed in collaboration with a network of transcranial magnetic stimulation&nbsp;medical experts.
The latest development will help Neuronetics meet new standards and improve treatment accessibility within the mental health industry.
<h3>About BMP Program</h3>
Better Me Provider Program is an extensive commercial initiative to support practices committed to meeting patient care and responsiveness standards. These standards are developed in collaboration with TMS medical experts, ensuring prompt response times by a dedicated NeuroStar coordinator, who advises patients about the benefits of the entire course of NeuroStar treatment, along with optimizing websites and social media content to educate patients. It is designed to help people with major depressive disorder, obsessive-compulsive disorder, and anxious depression.
<h3>More on the News</h3>
In the initial days of the trial, the BMP program showed success by significantly increasing provider efficiency and responsiveness.
The trial result validated that the BMP program significantly accelerated patient engagement by swiftly addressing interested patients. Through advanced training of the providers and improved response time, the company is expecting to treat more patients in need of life-changing therapy.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c6/70069.jpg?v=1098905618" /> 
Image Source: Zacks Investment Research
<h3>Industry Prospects</h3>
Per a report&nbsp;from Skyquest, the global Mental Health market was valued at $399.6 billion in 2022 and is expected to grow $544.6 billion by 2031, at a CAGR of 3.5% during the period. The primary factors influencing the global market include the increasing prevalence of mental health disorders worldwide and advancements in technology and research, which have led to the development of innovative treatment options. The growing awareness and acceptance of mental health issues also contribute to the market&#39;s growth.
Looking at the market potential, Neuronetics&#39; latest development is thoughtful and well-timed.
<h3>Other Notable Developments</h3>
Earlier this year, Neuronetics announced the FDA clearance of NeuroStar Advanced Therapy for usage as a supplement to treat MDD in adolescents aged between 15 years and 21 years. NeuroStar is the first and only FDA-approved transcranial magnetic stimulation treatment available for this age group.
In March 2024, Neuronetics entered into an expanded commercial partnership with Transformations Care Network (TCN), a mental health care provider. The company will supply new TMS equipment to TCN. This partnership marks a significant advancement in the field of mental health treatment, particularly for patients suffering from MDD and treatment-resistant depression.
<h3>Price Performance</h3>
In the past year, STIM&#39;s shares have lost 21.2% against the industry&#39;s 3.1% growth.
<h3>Zacks Rank and Key Picks</h3>
Neuronetics currently carries a Zacks Rank #3 (Hold).&nbsp;
Some better-ranked stocks in the broader medical space are Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>), The Joint Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jynt#NASDAQ">JYNT</a>) and Medpace Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>). While Hims &amp; Hers and The Joint sport a Zacks Rank #1 (Strong Buy) each, Medpace Holdings carries a Zacks Rank #2 (Buy) at present.&nbsp;
The Hims &amp; Hers Heath stock has surged 135.1% in the past year. Estimates for the company&#39;s 2024 earnings have moved north by 5.6% to 19 cents per share in the past 30 days.
HIMS&#39; earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for The Joint&#39;s 2024 earnings per share have remained constant at 21 cents in the past 30 days. Shares of JYNT have surged 37.4% year to date against the industry&#39;s 3.6% decline.
In the last reported quarter, JYNT delivered an earnings surprise of 300%. It has a trailing four-quarter average earnings surprise of 18.75%.
Estimates for Medpace&#39;s 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have surged 70.4% in the past year compared with the industry&#39;s 5.3% growth.
MEDP&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
<a href="https://www.zacks.com/stock/news/2296194/neuronetics-stim-expands-neurostar-portfolio-with-new-launch?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2296194">To read this article on Zacks.com click here.</a>

Penny Stocks

STIM

Neuronetics Expands NeuroStar Portfolio With New Launch

B. Riley Securities analyst Jeff Van Sinderen maintains Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) with a Buy and raises the price target from $12 to $20.

B. Riley Securities Maintains Buy on Joint, Raises Price Target to $20

WIIM

Joint shares are trading higher after the company reported better-than-expected Q1 financial results and reiterated FY23 system-wide sales guidance. Also, Roth MKM reiterated a Buy rating on the stock and raised its price target from $13 to $16.

Roth MKM analyst George Kelly reiterates Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) with a Buy and raises the price target from $13 to $16.

Reiteration

Roth MKM Reiterates Buy on Joint, Raises Price Target to $16

The Joint Corp. Reiterated Guidance, 2024 System-Wide Sales Expected To Be $530M-$545M

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.01) by 700 percent. This is a 62.5 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $29.722 million which beat the analyst consensus estimate of $29.591 million by 0.44 percent. This is a 5.02 percent increase over sales of $28.301 million the same period last year.

Joint Q1 2024 GAAP EPS $0.06 Beats $(0.01) Estimate, Sales $29.722M Beat $29.591M Estimate

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday.
The Dow traded up 0.27% to 38,894.21 while the NASDAQ fell 0.51% to 16,190.52. The S&amp;P 500 also fell, dropping, 0.20% to 5,146.8.
Check This Out: <a href="https://www.benzinga.com/news/24/03/37556716/wall-streets-most-accurate-analysts-views-on-3-risk-off-stocks-with-over-5-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Risk Off Stocks With Over 5% Dividend Yields </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Real estate shares jumped by 0.9% on Friday.
In trading on Friday, information technology shares fell by 1.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Nonfarm payrolls beat economist estimates, coming at 275,000 in February compared to the expected 200,000. The unemployment rate rose from 3.7% to 3.9%, surprising estimates of 3.7%.
Average hourly wages grew at a 0.1% monthly pace in February, easing from the downwardly revised 0.5% growth in January, and below the expected 0.3%.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Willdan Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wldn#NASDAQ">WLDN</a>) shares shot up 25% to $24.85 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years.
Shares of The Joint Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jynt#NASDAQ">JYNT</a>) got a boost, surging 31% to $11.94 following fourth-quarter results.
Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares were also up, gaining 134% to $1.54 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) shares dropped 82% to $3.3650 after the company announced its PHOENIX phase 3 trial of AMX0035 for amyotrophic lateral sclerosis did not meet its primary endpoint and there was no statistical significance seen in secondary endpoints.
Shares of AerSale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asle#NASDAQ">ASLE</a>) were down 27% to $6.82 after the company reported worse-than-expected fourth-quarter financial results.
BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) was down, falling 32% to $2.5750 after the company reported worse-than-expected fourth-quarter financial results.
Also Check This Out:<a href="https://www.benzinga.com/news/24/03/37557834/cisco-robinhood-and-2-other-stocks-insiders-are-selling"> Cisco, Robinhood And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 1.5% to $77.73 while gold traded up 1% at $2,186.90.
Silver traded down 0.2% to $24.54 on Friday while copper fell 1.1% to $3.8840.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 gained 0.02%, London&rsquo;s FTSE 100 fell 0.43% while Spain&rsquo;s IBEX 35 Index rose 0.13% The German DAX fell 0.16% French CAC 40 rose 0.15% while Italy&rsquo;s FTSE MIB Index fell 0.04%.
The eurozone economy stagnated during the fourth quarter compared to a 0.1% decline in the prior three-month period. French trade deficit increased to &euro;7.4 billion in January from &euro;6.4 billion in the prior month. Spanish industrial output declined by 0.6% year-over-year in January. Producer prices in Germany declined by 4.4% year-over-year in January, while industrial output increased by 1.0% month-over-month for January.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Friday, with Japan&rsquo;s Nikkei 225 gaining 0.23%, Hong Kong&rsquo;s Hang Seng Index gaining 0.76% and China&rsquo;s Shanghai Composite Index gaining 0.61%.
The gauge for Japan&rsquo;s service <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a> climbed to 51.3 in February versus prior month&rsquo;s reading of 50.2. The index of leading economic indicators in Japan fell to 109.9 in January versus a revised reading of 110.5 in December, while index of coincident economic indicators fell to 110.2 in January versus a revised 116.0 in the previous month. Household spending in Japan dipped by 6.3% year-over-year in January.
&nbsp;
<h3>Economics</h3>
&nbsp;
Nonfarm payrolls beat economist estimates, coming at 275,000 in February compared to the expected 200,000.
The unemployment rate rose from 3.7% to 3.9%, surprising estimates of 3.7%.
Average hourly wages grew at a 0.1% monthly pace in February, easing from the downwardly revised 0.5% growth in January, and below the expected 0.3%.
The total number of active U.S. oil rigs fell by 1 rig this week, Baker Hughes Inc reported.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37556718/top-3-industrials-that-are-preparing-to-pump-in-q1"> Top 3 Industrials That Are Preparing To Pump In Q1</a>

Eurozone

Commodities

Small Cap

Global

Intraday Update

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ASLE

BBAI

WLDN

Dow Gains Over 100 Points; AerSale Shares Plunge After Q4 Results

Shares of Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) fell sharply during Friday&rsquo;s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Marvell said fourth-quarter revenue increased 1% year-over-year to $1.427 billion, which beat the consensus estimate of $1.42 billion. The chip designer reported quarterly earnings of 46 cents per share, which was in line with analyst estimates.
Marvell sees first-quarter revenue of $1.15 billion, plus or minus 5%, versus estimates of $1.371 billion. The company sees first-quarter adjusted earnings of 23 cents per share, plus or minus 5 cents per share, versus estimates of 40 cents per share. The company authorized a $3 billion buyback.
Marvell Technology shares dipped 9.6% to $76.91 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) jumped 140% to $2.6899 after dipping 18% on Thursday.
Psyence Biomedical Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbm#NASDAQ">PBM</a>) shares climbed 139% to $3.0350. Psyence Biomedical recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study.
Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares jumped 138% to $1.57 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia.
MIRA Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mira#NASDAQ">MIRA</a>) shares climbed 48.5% to $1.36. MIRA Pharmaceuticals, last month, announced a research collaboration with Pharmaseed to research and evaluate Ketamir for patients with major depressive disorder and post-traumatic stress disorder.
CERo Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cero#NASDAQ">CERO</a>) shares climbed 35.4% to $4.17 after surging over 20% on Thursday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients.
Willdan Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wldn#NASDAQ">WLDN</a>) gained 30.4% to $25.89 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years.
The Joint Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jynt#NASDAQ">JYNT</a>) gained 29% to $11.80 following fourth-quarter results.
Smith &amp; Wesson Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swbi#NASDAQ">SWBI</a>) jumped 25.8% to $16.91 after the company reported better-than-expected third-quarter financial results.
Research Frontiers Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/refr#NASDAQ">REFR</a>) climbed 25.6% to $1.42 following fourth-quarter results.
Gulf Island Fabrication, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gifi#NASDAQ">GIFI</a>) shares gained 24.1% to $6.43 after the company reported a year-over-year increase in fourth-quarter revenue results.
Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) gained 22.7% to $6.89 after the company announced it published its consolidated annual accounts for 2023.
DoubleDown Interactive Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddi#NASDAQ">DDI</a>) gained 21.6% to $14.25.
Dogness (International) Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dogz#NASDAQ">DOGZ</a>) gained 18.6% to $7.98.
Kidpik Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pik#NASDAQ">PIK</a>) gained 18.3% to $3.0177.
America&#39;s Car-Mart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmt#NASDAQ">CRMT</a>) jumped 16.5% to $72.56 following third-quarter results.
Porch Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prch#NASDAQ">PRCH</a>) rose 16.1% to $3.6099 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance.
Samsara Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iot#NYSE">IOT</a>) gained 14.3% to $39.28 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance above estimates.
Viracta Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/virx#NASDAQ">VIRX</a>) shares gained 13.5% to $0.9200 following fourth-quarter results.
Aeva Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeva#NASDAQ">AEVA</a>) rose 12.6% to $1.34.
Adaptimmune Therapeutics plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adap#NASDAQ">ADAP</a>) gained 12.1% to $1.95. Adaptimmune Therapeutics recently reported better-than-expected quarterly EPS results.
HCI Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hci#NYSE">HCI</a>) gained 11.3% to $110.42 after the company reported better-than-expected fourth-quarter financial results.
NuScale Power Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smr#NYSE">SMR</a>) jumped 10.5% to $4.9289.
Redfin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdfn#NASDAQ">RDFN</a>) jumped 9.6% to $7.10.
reAlpha Tech Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aire#NASDAQ">AIRE</a>) rose 8.8% to $1.3599. reAlpha Tech, last month, appointed Michael Frenz as CFO and Mike Logozzo as President and COO.
Carnival Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccl#NYSE">CCL</a>) gained 5% to $16.44.
<h3>Losers</h3>
Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) shares fell 80.7% to $3.6596 after the company announced its PHOENIX phase 3 trial of AMX0035 for amyotrophic lateral sclerosis did not meet its primary endpoint and there was no statistical significance seen in secondary endpoints.
BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) fell 30.8% to $2.6006 after the company reported worse-than-expected fourth-quarter financial results.
Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) tumbled 28.6% to $0.0819.
Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 27.7% to $7.95.
Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) fell 26.3% to $5.45.
Immuron Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrn#NASDAQ">IMRN</a>) shares dipped 24.7% to $3.4250 after jumping 161% on Thursday.
AerSale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asle#NASDAQ">ASLE</a>) fell 24.4% to $7.11 after the company reported worse-than-expected fourth-quarter financial results.
CarParts.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prts#NASDAQ">PRTS</a>) fell 24.3% to $1.8999 following fourth-quarter results.
Mobix Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mobx#NASDAQ">MOBX</a>) fell 20.1% to $1.39.
Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) fell 19% to $0.8001 after surging 28% on Thursday. Nxu recently announced it successfully charged a Tesla Cybertruck.
Brera Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brea#NASDAQ">BREA</a>) shares fell 16.9% to $1.62. Brera Holdings shares jumped 91% on Thursday after the company announced that its Executive Chairman, Daniel McClory, acquired a majority stake in the company. 
Custom Truck One Source, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctos#NYSE">CTOS</a>) dipped 15.3% to $5.26 after the company reported mixed quarterly financial results.
Nexalin Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxl#NASDAQ">NXL</a>) fell 15.1% to $0.4627. Nexalin Technology recently announced results of a clinical study of its Gen-2 tACS device for the treatment of chronic insomnia.
Runway Growth Finance Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rway#NASDAQ">RWAY</a>) fell 13.5% to $11.68 following downbeat quarterly results.
Domo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/domo#NASDAQ">DOMO</a>) fell 12.7% to $9.92 after the company issued soft first-quarter and FY25 guidance.
MediaAlpha, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/max#NYSE">MAX</a>) declined 12.4% to $19.05 after the company announced a secondary offering of 3 million shares.
Genesco Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gco#NYSE">GCO</a>) fell 11.7% to $25.84 after the company&#39;s reported a fourth-quarter EPS miss and issued weak FY25 guidance.
Delek Logistics Partners, LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dkl#NYSE">DKL</a>) fell 11.3% to $39.51 after the company priced a public offering of 3,116,884 common units at $38.50 per unit.
Grom Social Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grom#NASDAQ">GROM</a>) fell 11% to $1.13 after jumping 65% on Thursday. The company announced that it entered into a non-binding letter of intent to acquire Arctic7.
Traeger, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cook#NYSE">COOK</a>) fell 10.5% to $2.11 after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued FY24 revenue guidance below estimates.
Aquestive Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aqst#NASDAQ">AQST</a>) dipped 10% to $5.11 following fourth-quarter results.
Petr&oacute;leo Brasileiro S.A. - Petrobras (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbr#NYSE">PBR</a>) shares fell 9.6% to $15.10 as the company reported a 6.3% year-over-year decline in its fourth-quarter net recurring profit.
Costco Wholesale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) fell 7.5% to $727.08 following mixed second-quarter results.
MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) declined 6.4% to $385.82 after the company issued weak FY25 guidance.
Icahn Enterprises L.P. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iep#NASDAQ">IEP</a>) fell 4.7% to $17.85.
RadNet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>) dipped 4.1% to $46.54. RadNet priced its public offering of 4.55 million common stock at $44 per share.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37553898/cramer-says-sprout-social-is-in-a-hot-spot-but-this-energy-stock-is-too-down-and-out"> Cramer Says Sprout Social Is In A &#39;Hot Spot,&#39; But This Energy Stock Is &#39;Too Down And Out&#39; </a>

Movers

ADAP

AEVA

AIMD

AIRE

AQST

BREA

CERO

COOK

COST

CRML

CRMT

CTOS

DOGZ

DOMO

EGOX

GIFI

GRFS

GROM

IMRN

MIRA

MOBX

MRVL

PRCH

PRTS

RDFN

RDNT

REFR

RWAY

SWBI

SWVL

VIRX

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Joint shares are trading higher after the company reported Q4 financial results.

<h3>Gainers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 137.8% to $3.02 during Friday's regular session. The market value of their outstanding shares is at $40.4 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock moved upwards by 91.96% to $2.15. The company's market cap stands at $10.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares increased by 34.75% to $1.28. The company's market cap stands at $18.9 million. </li>
<li>Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) stock rose 29.1% to $11.8. The market value of their outstanding shares is at $174.1 million. The company's, Q4 earnings came out yesterday. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock rose 25.11% to $8.32. The market value of their outstanding shares is at $89.3 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) stock increased by 19.69% to $6.71. The market value of their outstanding shares is at $4.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) shares declined by 81.5% to $3.52 during Friday's regular session. The market value of their outstanding shares is at $238.2 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock fell 25.94% to $3.37. The market value of their outstanding shares is at $19.1 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 22.94% to $7.09. The company's market cap stands at $1.1 billion. </li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) shares fell 16.55% to $12.51. The market value of their outstanding shares is at $42.7 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock declined by 14.27% to $4.84. The market value of their outstanding shares is at $64.4 million. </li>
<li>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) stock declined by 13.72% to $3.46. The market value of their outstanding shares is at $79.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

EFTR

LTRN

TSBX

ZJYL

12 Health Care Stocks Moving In Friday's Intraday Session

The Joint Corp. Sees FY24 System-Wide Sales $530M-$545M; System-Wide Comp Sales For All Clinics Open 13 Months Or More 4%- Mid-Single Digits; New Franchised Clinic Openings Excluding The Impact Of Refranchised Clinics 60-75

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly losses of $(0.750) per share which missed the analyst consensus estimate of $0.010 by 7600 percent. The company reported quarterly sales of $30.614 million which beat the analyst consensus estimate of $29.082 million by 5.27 percent. This is a 10.07 percent increase over sales of $27.813 million the same period last year.

Joint Q4 2023 GAAP EPS $(0.750) Misses $0.010 Estimate, Sales $30.614M Beat $29.082M Estimate

AFCG

ALIM

AMTX

AOUT

ARBE

ARCT

ARHS

ASPS

AVGO

BBCP

BILI

BITF

BNED

BURL

CHMI

CIEN

CINT

CLAR

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

DBVT

DLTH

DOCU

DSGR

DXPE

ELUT

EOLS

EVGN

EYPT

FCEL

FNKO

GEVO

GRND

GRNT

GWRE

HBIO

ISDR

LCTX

LMNR

LOCO

LUMO

LVRO

METC

MGNX

MKFG

NAPA

NCSM

NDLS

NEPH

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PowerShares Dynamic Industrials Sector Portfolio

PROF

PSFE

RDVT

REAX

SDPI

SGHT

Earnings Scheduled For March 7, 2024

The Joint Corp. Needs To Speed Up Its Refranchising Process

The Joint Corp names Sanjiv Razdan as CEO

Craig-Hallum analyst Jeremy Hamblin maintained a Hold rating on Joint (JYNT – Research Report) today. The company's shares closed yesterday at $10....

Craig-Hallum Keeps Their Hold Rating on Joint (JYNT)

In a report released today, Ryan Meyers from Lake Street maintained a Buy rating on Joint (JYNT – Research Report), with a price target of $20.00. ...

Lake Street Remains a Buy on Joint (JYNT)

Joint ( ($JYNT) ) has issued an announcement. The Joint Corp. has announced the resignation of Peter D. Holt as President, CEO, and board member, e...

Joint Announces Leadership Change and New CEO Appointment

In a report released today, Jeremy Hamblin from Craig-Hallum maintained a Hold rating on Joint (JYNT – Research Report). The company's shares close...

Craig-Hallum Remains a Hold on Joint (JYNT)

Joint GAAP EPS of -$0.21 misses by $0.22, revenue of $30.19M beats by $1.81M

Reports Q3 revenue $30.2M, consensus $28.38M. Reports system-wide comp sales2 of 4%…"As the category leader with a premier national brand, attracti...

Joint Corp. reports Q3 EBITDA $2.4M vs. $2.9M last year

The Joint Corp. (JYNT) Q3 2024 Earnings Call Transcript

Maxim Group analyst Anthony Vendetti has maintained their neutral stance on JYNT stock, giving a Hold rating on November 8. Anthony Vendetti has gi...

Hold Rating Amidst Uncertainty and Transitional Challenges in Q3 2024

Press Releases

The Joint Corp. to Participate in the 7th Annual B. Riley Securities Consumer & TMT Conference

SUCCESS Magazine Names The Joint Chiropractic one of the Top 50 Franchises

The Joint Corp. Announces New Senior Vice President of Human Resources

The Joint Chiropractic Celebrates 25 Years of Making Quality Chiropractic Care Accessible

The Joint Chiropractic Ranks No. 150 on the Franchise Times Top 400

The Joint Corp. Appoints Sanjiv Razdan President and Chief Executive Officer

The Joint Corp. Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

The Joint Corp. to Host Conference Call on Thursday, November 7th to Discuss Third Quarter 2024 Results

The Joint Chiropractic is Named the Official Chiropractor of Grand Canyon University Athletics

Comments

Joint

Notizie

Ultime notizie per Joint (NASDAQ:JYNT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO